|
| 36672456 | Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for â¿¥5 Years in the RESONATE-2 Study. | Cancers (Basel) | 2023 |
| 37871223 | Expression signature of human endogenous retroviruses in chronic lymphocytic leukemia. | Proc Natl Acad Sci U S A | 2023 |
| 37315225 | Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. | Blood Adv | 2023 |
| 37282671 | Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. | Clin Cancer Res | 2023 |
| 36944183 | Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway. | Oncotarget | 2023 |
| 37279436 | Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia. | J Clin Oncol | 2023 |
| 37029329 | Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. | Breast Cancer Res Treat | 2023 |
| 36624313 | Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. | Nat Med | 2023 |
| 36617990 | Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8Â Years: A Plain Language Summary. | Future Oncol | 2023 |
| 34285341 | Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. | Leukemia | 2022 |
| 35406490 | Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2022 |
| 35580162 | ROR1: an orphan becomes apparent. | Blood | 2022 |
| 35377947 | Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. | Blood Adv | 2022 |
| 35605176 | Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. | Blood | 2022 |
| 35361793 | cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. | Nat Commun | 2022 |
| 35418613 | High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. | Leukemia | 2022 |
| 35714675 | NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. | J Natl Compr Canc Netw | 2022 |
| 35747847 | B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by <i>TP53</i> Abnormalities. | Hemasphere | 2022 |
| 36551520 | Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's Syndrome. | Cancers (Basel) | 2022 |
| 35903706 | Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. | Front Oncol | 2022 |
| 35927489 | Molecular map of chronic lymphocytic leukemia and its impact on outcome. | Nat Genet | 2022 |
| 35983732 | Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. | Leuk Lymphoma | 2022 |
| 35014928 | Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. | Leuk Lymphoma | 2022 |
| 35064090 | A large fraction of trisomy 12, 17p<sup>-</sup>, and 11q<sup>-</sup> CLL cases carry unidentified microdeletions of <i>miR-15a/16-1</i>. | Proc Natl Acad Sci U S A | 2022 |
| 35196370 | Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. | Blood | 2022 |
| 35230971 | Modulation of RNA splicing associated with Wnt signaling pathway using FD-895 and pladienolide B. | Aging (Albany NY) | 2022 |
| 35020831 | Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. | Blood | 2022 |
| 35103064 | Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. | Adv Hematol | 2022 |
| 34699592 | Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. | Blood | 2022 |
| 33097837 | Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. | Leukemia | 2021 |
| 33730844 | Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. | Haematologica | 2021 |
| 33611131 | Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. | Leuk Res | 2021 |
| 33689703 | A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. | Cancer Cell | 2021 |
| 33604581 | Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. | Blood Cancer Discov | 2021 |
| 34939038 | Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. | Nat Cancer | 2021 |
| 34618601 | Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. | J Clin Oncol | 2021 |
| 34398557 | Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. | Cancer J | 2021 |
| 34686499 | Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell-Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. | Cancer Res | 2021 |
| 34075408 | Exploring the pathways to chronic lymphocytic leukemia. | Blood | 2021 |
| 34115103 | Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. | Blood | 2021 |
| 34112698 | Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. | Cancer Discov | 2021 |
| 34083230 | Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. | Clin Cancer Res | 2021 |
| 33171493 | miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. | Blood | 2021 |
| 33451349 | Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. | J Hematol Oncol | 2021 |
| 31048356 | Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. | Haematologica | 2020 |
| 31996785 | Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. | Oncogene | 2020 |
| 31992855 | NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. | Cell Death Differ | 2020 |
| 32023533 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32888452 | Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2020 |
| 32938797 | Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. | Sci Transl Med | 2020 |